Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Mango consumption on ulcerative colitis and bone parameters in animal models: Studies

Three new mango-related studies were presented this week at the 2014 Federation of American Societies for Experimental Biology (FASEB) in San Diego, revealing initial findings on the effects of mango consumption on ulcerative colitis and bone parameters in animal models.

1 May 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure.

23 Apr 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

26 Mar 2014

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

6 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.

27 Feb 2014

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

24 Feb 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1

21 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year.

10 Feb 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

New, "designer" dietary fiber may eliminate side effects of current IBS treatment

A newly-developed, "designer" dietary fiber with an added potential prebiotic effect may eliminate the side effects of current treatment for Irritable Bowel Syndrome which affects 10-20 percent of the population, disproportionately women.

20 Jan 2014

Study shows high-fiber diet reduces risk of colon problems

Scientists have more reasons for you to eat fiber and not abuse antibiotics.

17 Jan 2014

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April.

9 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Mango consumption on ulcerative colitis and bone parameters in animal models: Studies

Adhesion molecule offers promising therapeutic target for preventing colitis

Studies identify 2 genes highly associated with IBD

Actavis gets favorable ruling in patent suit against generic Lialda

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

Important facts about colorectal cancer

Scientists map key elements of immune overreaction triggered by influenza virus infection

TSRI scientists describe severe immune overreaction caused by flu infections

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Ulcerative colitis patients not satisfied with current treatments according to new study

Alvogen launches Inflectra into Central and Eastern Europe

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

New, "designer" dietary fiber may eliminate side effects of current IBS treatment

Study shows high-fiber diet reduces risk of colon problems

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in